Welcome to our dedicated page for MTWD news (Ticker: MTWD), a resource for investors and traders seeking the latest updates and insights on MTWD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MTWD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MTWD's position in the market.
Metwood (OTC PINK:MTWD) announced on July 18, 2022, that its subsidiary, Emerge Nutraceuticals, has signed a memorandum of understanding (MOU) to acquire Cholesterade from Go Epic Health, Inc.. The deal involves undisclosed shares and is expected to finalize in the 3rd quarter of 2022. Cholesterade is an acai-fiber-based supplement proven to reduce cholesterol over eight weeks. Created by Dr. J. Robert Cade, it offers a natural alternative to statins. This acquisition aims to enhance Emerge Nutraceuticals' product offerings in the health supplement market.
FAQ
What is the market cap of MTWD (MTWD)?
